Changing TACTICS in intermediate HCC: TACE plus sorafenib.
作者信息
Radu Pompilia, Dufour Jean-François
机构信息
University Clinic for Visceral Surgery and Medicine, University of Bern, Inselspital, Bern, Switzerland.
University Clinic for Visceral Surgery and Medicine, University of Bern, Inselspital, Bern, Switzerland
出版信息
Gut. 2020 Aug;69(8):1374-1376. doi: 10.1136/gutjnl-2020-320692. Epub 2020 Mar 13.
Abstract
摘要
相似文献
1
Changing TACTICS in intermediate HCC: TACE plus sorafenib.中晚期肝癌治疗策略的改变：经动脉化疗栓塞术（TACE）联合索拉非尼
Gut. 2020 Aug;69(8):1374-1376. doi: 10.1136/gutjnl-2020-320692. Epub 2020 Mar 13.
2
Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.索拉非尼或安慰剂联合载多柔比星微球 TACE 治疗中晚期 HCC：SPACE 试验。
J Hepatol. 2016 May;64(5):1090-1098. doi: 10.1016/j.jhep.2016.01.012. Epub 2016 Jan 22.
3
The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.经动脉化疗栓塞联合索拉非尼与索拉非尼单药治疗巴塞罗那临床肝癌分期 B/C 期患者的安全性和有效性。
BMC Cancer. 2017 Sep 12;17(1):645. doi: 10.1186/s12885-017-3545-5.
4
Texture analysis of intermediate-advanced hepatocellular carcinoma: prognosis and patients' selection of transcatheter arterial chemoembolization and sorafenib.中晚期肝细胞癌的纹理分析：经动脉化疗栓塞术和索拉非尼治疗的预后及患者选择
Oncotarget. 2017 Jun 6;8(23):37855-37865. doi: 10.18632/oncotarget.13675.
5
Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.索拉非尼对经动脉化疗栓塞术难治的中期肝细胞癌患者的疗效。
Oncology. 2014;87(6):330-41. doi: 10.1159/000365993. Epub 2014 Sep 6.
6
Transarterial chemoembolization and sorafenib in hepatocellular carcinoma.经动脉化疗栓塞术与索拉非尼治疗肝细胞癌
Expert Rev Anticancer Ther. 2014 Jul;14(7):831-45. doi: 10.1586/14737140.2014.920694. Epub 2014 May 22.
7
Efficacy of transcatheter arterial chemoembolization followed by sorafenib for intermediate/advanced hepatocellular carcinoma in patients in Japan: a retrospective analysis.经动脉化疗栓塞术联合索拉非尼治疗日本中晚期肝细胞癌患者的疗效：一项回顾性分析。
Clin Drug Investig. 2015 Nov;35(11):751-9. doi: 10.1007/s40261-015-0333-3.
8
Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.与经动脉化疗栓塞术或索拉非尼相比，肝切除术治疗伴有门静脉癌栓的肝细胞癌的生存结局。
Clin Mol Hepatol. 2016 Mar;22(1):160-7. doi: 10.3350/cmh.2016.22.1.160. Epub 2016 Mar 28.
9
Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.索拉非尼联合经动脉化疗栓塞可提高不可切除肝细胞癌患者的生存率：一项倾向评分匹配研究。
J Dig Dis. 2013 Apr;14(4):181-90. doi: 10.1111/1751-2980.12038.
10
The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma.经导管动脉化疗栓塞联合放疗治疗晚期肝细胞癌的可行性。
Liver Int. 2014 May;34(5):795-801. doi: 10.1111/liv.12445. Epub 2014 Jan 12.
引用本文的文献
1
Role of immune checkpoint inhibitor combinations in resectable and unresectable, embolization-eligible hepatocellular carcinoma.免疫检查点抑制剂联合疗法在可切除和不可切除、适合栓塞治疗的肝细胞癌中的作用
Ther Adv Med Oncol. 2025 Jul 24;17:17588359251357719. doi: 10.1177/17588359251357719. eCollection 2025.
2
Effectiveness of sorafenib in treating intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.索拉非尼治疗经肝动脉化疗栓塞治疗抵抗的中期肝细胞癌患者的疗效。
BMC Cancer. 2024 Nov 28;24(1):1466. doi: 10.1186/s12885-024-13199-1.
3
Transcatheter arterial chemoembolization plus Sorafenib versus transcatheter arterial chemoembolization plus Lenvatinib for intermediate hepatocellular carcinoma.经导管动脉化疗栓塞术联合索拉非尼与经导管动脉化疗栓塞术联合仑伐替尼治疗中期肝细胞癌。
Sci Rep. 2024 Oct 27;14(1):25616. doi: 10.1038/s41598-024-74801-x.
4
Local and Regional Therapies for Hepatocellular Carcinoma and Future Combinations.肝细胞癌的局部和区域治疗及未来联合治疗
Cancers (Basel). 2022 May 17;14(10):2469. doi: 10.3390/cancers14102469.
5
Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma.经动脉化疗栓塞联合免疫检查点抑制剂和酪氨酸激酶抑制剂治疗肝细胞癌的安全性和有效性
Front Oncol. 2022 Jan 13;11:657512. doi: 10.3389/fonc.2021.657512. eCollection 2021.
6
Relevance of EGFR Between Serum VEGF and MMP-9 in Primary Hepatocellular Carcinoma Patients with Transarterial Chemoembolization.原发性肝癌经动脉化疗栓塞患者血清血管内皮生长因子和基质金属蛋白酶-9 中表皮生长因子受体的相关性
Onco Targets Ther. 2020 Sep 23;13:9407-9417. doi: 10.2147/OTT.S257271. eCollection 2020.
本文引用的文献
1
Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.随机、多中心前瞻性试验：比较经动脉化疗栓塞（TACE）联合索拉非尼与单纯 TACE 治疗肝细胞癌患者的疗效：TACTICS 试验。
Gut. 2020 Aug;69(8):1492-1501. doi: 10.1136/gutjnl-2019-318934. Epub 2019 Dec 4.
2
2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.2018 韩国肝癌协会-韩国国家癌症中心肝细胞癌管理实践指南。
Gut Liver. 2019 May 15;13(3):227-299. doi: 10.5009/gnl19024.
3
Radiologic criteria of response to systemic treatments for hepatocellular carcinoma.肝细胞癌全身治疗反应的放射学标准。
Hepat Oncol. 2017 Oct;4(4):129-137. doi: 10.2217/hep-2017-0018. Epub 2017 Nov 17.
4
Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.经动脉化疗栓塞联合索拉非尼治疗不可切除肝细胞癌的系统评价与Meta分析
BMC Gastroenterol. 2018 Sep 4;18(1):138. doi: 10.1186/s12876-018-0849-0.
5
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.肝细胞癌的诊断、分期及管理：美国肝病研究协会2018年实践指南
Hepatology. 2018 Aug;68(2):723-750. doi: 10.1002/hep.29913.
6
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.索拉非尼联合经动脉化疗栓塞治疗不可切除肝细胞癌（TACE 2）：一项随机安慰剂对照、双盲、3 期临床试验。
Lancet Gastroenterol Hepatol. 2017 Aug;2(8):565-575. doi: 10.1016/S2468-1253(17)30156-5. Epub 2017 Jun 23.
7
Evolving role of Sorafenib in the management of hepatocellular carcinoma.索拉非尼在肝细胞癌治疗中的角色演变
World J Clin Oncol. 2017 Jun 10;8(3):203-213. doi: 10.5306/wjco.v8.i3.203.
8
Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.《亚太地区肝细胞癌管理临床实践指南：2017年更新版》
Hepatol Int. 2017 Jul;11(4):317-370. doi: 10.1007/s12072-017-9799-9. Epub 2017 Jun 15.
9
Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.索拉非尼或安慰剂联合载多柔比星微球 TACE 治疗中晚期 HCC：SPACE 试验。
J Hepatol. 2016 May;64(5):1090-1098. doi: 10.1016/j.jhep.2016.01.012. Epub 2016 Jan 22.
10
Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions.中危（BCLC B）期肝细胞癌患者的异质性：提出一种亚分类以促进治疗决策。
Semin Liver Dis. 2012 Nov;32(4):348-59. doi: 10.1055/s-0032-1329906. Epub 2013 Feb 8.
Zotero 插件